IDEAYA Biosciences Grants Stock Options to New Employees in Accordance with Nasdaq Rules

IDEAYA Biosciences Expands Workforce with Stock Options Grants

On October 30, 2025, IDEAYA Biosciences, a company specializing in precision medicine for oncology, took a significant step in expanding its workforce. The firm announced that it has authorized the granting of non-qualified stock options to two newly recruited employees, totaling an aggregate of 73,500 shares of common stock. This decision aligns with the guidelines set forth by Nasdaq Listing Rule 5635(c)(4).

The stock options are a part of IDEAYA’s 2023 Employment Inducement Incentive Award Plan, specifically designed to attract fresh talent who have not previously worked for the company. This plan reflects IDEAYA’s ongoing commitment to fostering an inclusive workplace, a move that is both strategic and essential in the highly competitive field of biotechnology.

Details of the Stock Options Granted

The granted stock options are priced at $31.60 per share, which coincides with the market closing price on the grant date as recorded by The Nasdaq Global Select Market. These options have an extended term of 10 years, allowing employees ample time to benefit from their stock options. The vesting schedule is set to unfold over four years—25% of the options will vest on the first anniversary of the vested date, while the remaining 75% will vest in equal monthly increments over the subsequent three years.

Continued employment with IDEAYA is pivotal for the vesting of these stock options, emphasizing the company’s focus on retaining talent and ensuring employee commitment.

About IDEAYA Biosciences

IDEAYA Biosciences is increasingly recognized in the realm of cancer therapies, delivering transformative solutions through their cutting-edge precision medicine strategies. The company integrates vast expertise across numerous domains including small-molecule drug discovery, structural biology, and bioinformatics. IDEAYA’s operational prowess in recognizing and verifying translational biomarkers is crucial in its mission to develop therapies that are not only innovative but also can be personalized to the genetic underpinnings of various cancers.

The company's notable pipeline of product candidates focuses on groundbreaking approaches, particularly in synthetic lethality and antibody-drug conjugates (ADCs), targeting molecularly defined solid tumor indications. The ultimate aim is to pivot the course of the disease for patients while benchmarks of success anticipate improved clinical outcomes.

As IDEAYA continues to broaden its horizons with new talent and advanced opportunities, it reinforces its vision toward redefining precision oncology—increasing accessibility to targeted therapies and enhancing the lives of individuals facing cancer.

For stakeholders and interested parties, IDEAYA is poised for influence not just within the biopharmaceutical space but as a vanguard for precision health worldwide.

Conclusion

IDEAYA Biosciences is keen on not just discovering and developing new medications but is also committed to attracting and retaining top-tier talents necessary for fulfilling its mission. The recent stock options grants symbolize a dual commitment—the advancement of its workforce and the ongoing battle against cancer through precision medicine.

For more details or inquiries regarding IDEAYA's strategic initiatives, contact:

Joshua Bleharski, Ph.D.
Chief Financial Officer
[Contact Email]

By reinforcing its team with competitive compensation structures, IDEAYA is enhancing its capabilities in delivering innovative cancer care therapies.